Clinical Trials
12 trialsNCT04074785 2025-08-17
SCCC-06319
University of Texas Southwestern Medical Center
Phase EARLY_PHASE1 Terminated
NCT03698162 2025-08-05
Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases
University of Southern California
Phase NA Terminated
NCT02521051 2025-05-13
Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer
Massachusetts General Hospital
Phase 1/2 Terminated
NCT01814813 2025-01-24
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT02490878 2023-03-23
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT02343549 2022-11-03
A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)
Wake Forest University Health Sciences
Phase 2 Terminated
NCT01582152 2019-06-05
Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT01086345 2018-07-03
Radiosurgery Plus Bevacizumab in Glioblastoma
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Terminated
NCT01526837 2017-07-12
Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence
Brain & Spine Surgeons of New York
Phase 1 Terminated
NCT01105702 2016-08-04
Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma
NYU Langone Health
Phase 2 Terminated
NCT01189240 2015-12-14
RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT00393094 2012-07-13
Bevacizumab and Irinotecan to Treat Brain Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated